Restore Mind Medicine
Unkept Promises in Other
Clinical Trials
MindMed has repeatedly promised investors various trials which were quietly dropped without explanation.
From January 2021 until August of 2021, MindMed repeatedly told investors it was starting a trial with
micro dosing MM-120 and using digital medicine. This was in addition to the Phase Ila micro dosing trial
in ADHD. MindMed removed it from their deck without explanation.
In August and November of 2021, MindMed stated that it would conduct Phase lla trials using MM-120
for the treatment of "acute pain" and "chronic pain" in 2022. The acute pain trial was quietly dropped.
In June of 2022, MindMed announced that the chronic pain trial would start during the fourth quarter of
2022. No study was completed and MindMed dropped it from their investor presentations.
Puzzlingly, MindMed executives received a 100% completion rating on MindMed's clinical goals.
Source: Company SEC Filings, MindMed Press Releases, MindMed Investor Presentations.
41View entire presentation